Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Figs Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Figs Inc trades at $9.79 (market cap $1.62B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 5× Figs Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| BIO | FIGS | |
|---|---|---|
Market Cap | $8.04B | $1.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $17.12 |
52-Week Low | $241.71 | $5.81 |
Enterprise Value | $7.85B | $1.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FIGS trades at $10.00, down 0.4% on the day, with a bearish technical signal from moving averages but recent earnings beats. The company reported Q1 2026 revenue growth of 28% and raised full-year guidance, though net cash flow remains negative. Analyst consensus is a Buy with a $19.50 price target, implying significant upside from current levels.
The outlook is mixed: strong fundamentals and growth prospects support the bull case, but valuation is rich at a P/E of 45.45, and margin pressures from tariffs and spending pose risks. The stock's performance hinges on execution of global expansion and cost management amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
